Quantification of serum free light chain kappa and lambda by the SPAPLUS analyser

Clinical Biochemistry

Volumn 46, Issue 7-8, 2013, Pages 622-626

  Maisin, Diane ^a   Lepoutre, Thibault ^a   Gruson, Damien ^a   Wallemacq, Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Free light chains; Immunonephelometry; Immunoturbidimetry; Plasma cell dyscrasias

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOASSAY ANALYZER; IMMUNONEPHELOMETRY; LIGHT CHAIN; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; PATIENT MONITORING; PHOTOMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SERUM FREE LIGHT CHAIN KAPPA; SERUM FREE LIGHT CHAIN LAMBDA; TURBIDIMETRY; AUTOANALYSIS; BLOOD; EQUIPMENT; EVALUATION; PARAPROTEINEMIA; REPRODUCIBILITY;

AUTOANALYSIS; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; NEPHELOMETRY AND TURBIDIMETRY; PARAPROTEINEMIAS; REPRODUCIBILITY OF RESULTS;

EID: 84884791245     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.12.015     Document Type: Article

References (17)

1. Katzmann J.A. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009, 30:105-111.
2. Kyle R.A., Durie B.G., Rajkumar S.V., et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24:1121-1127.
3. Cohen A.D., Comenzo R.L. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010, 2010:287-294.
4. Dispenzieri A., Kyle R., Merlini G., et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23:215-224.
5. Kumar S., Dispenzieri A., Katzmann J.A., et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010, 116:5126-5129.
6. Bradwell A.R., Carr-Smith H.D., Mead G.P., et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001, 47:673-680.
7. Katzmann J.A., Clark R.J., Abraham R.S., et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002, 48:1437-1444.
8. Briand P.Y., Decaux O., Caillon H., Grosbois B., Le Treut A., Guenet L. Analytical performance of the serum free light chain assay. Clin Chem Lab Med 2010, 48:73-79.
9. Tate J., Bazeley S., Sykes S., Mollee P. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev 2009, 30:131-140.
10. Vercammen M., Meirlaen P., Broodtaerts L., Vande Broek I., Bossuyt X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta 2011, 412:1798-1804.
11. Tate J.R., Mollee P., Dimeski G., Carter A.C., Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007, 376:30-36.
12. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
13. Marshall G., Tate J., Mollee P. Borderline high serum free light chain kappa/lambda ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states. Am J Clin Pathol 2009, 132:309.
14. Hutchison C.A., Basnayake K., Cockwell P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol 2009, 5:621-628.
15. de Larrea C.F., Cibeira M.T., Elena M., et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 2009, 114:4954-4956.
16. Singhal S., Vickrey E., Krishnamurthy J., Singh V., Allen S., Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009, 114:38-39.
17. Katzmann J.A., Snyder M.R., Rajkumar S.V. Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. Clin Chem 2011, 57:1687-1692.